Behandeling van mitralisklepinsufficiëntie met een mitralisclip

• The consideration for treatment of mitral regurgitation is dependent on its underlying cause: degenerative or functional.
• The percutaneous MitraClip treatment is mostly suitable for patients with severe, symptomatic mitral regurgitation and additional risk factors, who therefore do not qualify for surgical treatment but still have a life expectancy of more than one year.
• The MitraClip treatment has undergone technical improvements in the past ten years and has a low rate of periprocedural and postprocedural complications.
• Patients with severe functional mitral regurgitation, a relatively preserved left ventricular function, and a limited left ventricular volume benefit most from a MitraClip treatment.
• The number of MitraClip procedures in the Netherlands is strongly increasing and has shown good results.
• Besides the development of the MitraClip and introduction of new devices, careful patient selection is the most important instrument to achieve better results.

Conflict of interest and financial support: potential conflicts of interest have been reported for this article.